Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
By E. Chiorean. 2012
637 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/f352ce76518798920aaa00c5aa0020594b70ba5d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pathology and Forensic Medicine
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Tumor angiogenesis and vascular normalization: alternative therapeutic targets (2017, background): “In patients bearing gastric cancer, the combination of bevacizumab with chemotherapy has significantly improved the progression-free survival and overall response [96].”
- Japanese gastric cancer treatment guidelines 2014 (ver. 4) (2016, methodology): “Capecitabine ? cisplatin combination is currently one of standard treatments overseas and was employed as a control group in global phase III studies, the ToGA trial [17] and AVAGAST trial [18].”
- Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. (2018, background): “[114] Advanced gastric cancer 774 Group 2 Placebo + Fluoropyrimidine– Cisplatin Group 2 PFS: 5.”
- Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (2022, methodology): “The combination of capecitabine and cisplatin (XP) is recognized as one of the standard treatments in other countries after its non-inferiority to the 5-FU/cisplatin combination (FP) was proven and has been used as a control group in several global phase III studies, such as the ToGA trial [50] and ”
- Japanese gastric cancer treatment guidelines 2018 (5th edition) (2020, methodology): “After its non-inferiority to the 5-FU/cisplatin combination (FP) had been proven, a combination of capecitabine and cisplatin (XP) became one of standard treatments overseas and was employed as a control group in several global phase III studies including the ToGA trial [37] and AVAGAST trial [43].”